Biology and chemistry details CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH)
In vitro and in vivo studies in animals have shown that the use of deuterated PUFAs can lower the peroxidation effects on producing atherosclerosis, control hyperlipidaemia, and reduce cholesterol levels in blood ( Although these are beneficial signals for human health, many questions are raised for the whole of the organisms health since the deuterated lipids will accumulate in a vast number of cells and in their membranes, as in the case of myelin, and will cause a significant alteration in the metabolism of the deuterated host organism ( It would therefore be crucial to re-think the use of deuterated lipids to counterweight lipid, especially PUFA, peroxidation, as their application may seem promising but can hide severe and unpredictable pathologies raised in the recipient host
Results depend heavily on baseline body composition, dietary adherence, exercise programming, sleep quality, stress management, genetic factors, and protocol compliance
Safety Considerations There are currently no published studies specifically examining the combination of CJC-1295 and Retatrutide in humans
